UW-Madison School of Pharmacy

Navigation Options

  • Mailing Address
  • K4/554
  • Clinical Science Center
  • 600 Highland Ave.
  • Madison, WI 53792

  • Office
  • K4/554 Clinical Science Center

  • Phone: 608-262-5549
  • Fax: 608-265-5421

  • Email: JMKolesar@pharmacy.wisc.edu

    Email Jill Kolesar


  • 3P Lab

photo

Jill M Kolesar, Pharm.D., B.C.P.S., FCCP, R.Ph.

Professor (CHS)
Director: 3P Analytical Instrumentation Laboratory, UWCCC

 

 

 


Dr. Kolesar's research involves the clinical pharmacology of anticancer and chemoprevention compounds.  She holds two patents for developing novel technologies for evaluating gene expression and point mutations and is a co-founder of Helix Diagnostics. She is a former member of the National Cancer Institutes's Adult Central IRB and is a member of the Board of Regents of the American College of Clinical Pharmacy. In addition, Dr. Kolesar chairs the Lung Cancer Biology Subcommittee for the Eastern Cooperative Oncology Group and serves on the core committess for the Thoracic and Biomarker Committees of ECOG.

Course Coordinator: 728-656

Faculty Supervisor: 3P Analytical Lab UW Carbone Cancer Center

Elected Member: ACCP Research Instute Board of Trustees

Co-Editor: Pharmacotherapy Principles and Practice

Co-Editor: Top 300 Drug Cards

Editorial Board: Journal of Clinical Oncology

Editorial Board: Journal of Oncology Pharmacy Practice

 

Background: Dr. Kolesar is the Director of the Analytical Instrumentation Laboratory for Pharmacokinetics, Pharmacodynamcis and Pharmacogenetics (3P) at the University of Wisconsin Carbone Cancer Center and a Professor (CHS) at the University of Wisconsin School of Pharmacy. She completed a specialty practice residency in oncology/hematology and 2 year fellowship in molecular oncology pharmacotherapy at the University of Texas Health Science Center in San Antonio. Dr Kolesar joined the UW faculty in 1996.

 

 

Education:

  • B.S. 1990 Pharmacy - University of Wisconsin
  • Pharm.D. 1993 - University of Texas Health Science Center in San Antonio
  • Residency 1994 Oncology/Hematology - University of Texas Health Science Center
  • Fellowship 1996 Molecular Oncology - University of Texas Health Science Center

Dr. Kolesar teaches in the area of hematology, oncology and pharmacogenomics.  She is a preceptor in the ASHP accrediated oncology specialty residency at UWHC and has trained numerous undergraduates, PharmD students, masters students, postdoctoral fellows and visiting scientists in her laboratory.  

She is the past recipeint of the Innovations in Teaching Award from  the American Association of Colleges of Pharmacy.  Jill serves on the editorial boards of the Journal of Clinical Oncology and the Journal of Oncology Pharmacy Practice. She is the co-editor of the textbooks; Pharmacogenomics Handbook, ACCP’s Pharmacogenomics: Applications to Patient Care, Pharmacotherapy: Principles and Practice and the Top 300 Prescription Drug Flash Cards

Highlighted Publications:
  • Sachidanandam K, Gayle AA, Robins HI, Kolesar JM Unexpected doxorubicin-induced cardiomyopathy in sisters. Int Canc Conf J 2012; 1: 15–18
  • Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby JE, Hohl R, Bailey H. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res (Phila). 2012 Apr;5(4):621-30.
  • Shin HC, Cho H, Lai TC, Kozak KR, Kolesar JM, Kwon GS. Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin. J Control Release. 2012 Oct 10;163(1):93-9.
  • Sachidanandam K, Gayle AA, Robins HI, Kolesar JM. Unexpected doxorubicin-mediated cardiotoxicity in sisters: Possible role of polymorphisms in histamine n-methyl transferase. J Oncol Pharm Pract. 2012 Nov 15
  • Ikeda R, Vermeulen LC, Lau E, Jiang Z, Saha S, Reichelderfer M, Kolesar JM Stability of infliximab in polyvinyl chloride bags. Am J Health Syst Pharm. 2012 Sep 1;69(17):1509-12
  • Kolesar J, Brundage RC, Pomplun M, Alberti D, Holen K, Traynor A, Ivy P, Wilding G. Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients.Cancer Chemother Pharmacol. 2011 Feb;67(2):393-400.
  • Liu G, Jeraj R, Vanderhoek M, Perlman S, Kolesar J, Harrison M, Simoncic U, Eickhoff J, Carmichael L, Chao B, Marnocha R, Ivy P, Wilding G Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate. Clin Cancer Res. 2011 Dec 15;17(24):7634-44. Epub 2011 Oct 28.
  • Liu G, Chen YH, Kolesar J, Huang W, Dipaola R, Pins M, Carducci M, Stein M, Bubley GJ, Wilding G. Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.Urol Oncol. 2011 Jul 22. [Epub ahead of print]
  • Shin HC, Alani AW, Cho H, Bae Y, Kolesar JM, Kwon GS. A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs. Mol Pharm. 2011 Aug 1;8(4):1257-65. Epub 2011 Jun 23.
  • Kolesar JM, Dahlberg SE, Marsh S, McLeod HL, Johnson DH, Keller SM, Schiller JH.The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncol Rep. 2011 Jun;25(6):1765-72. doi: 10.3892/or.2011.1249. Epub 2011 Apr 6.
  • Ramalingam SS, Lee JW, Belani CP, Aisner SC, Kolesar J, Howe C, Velasco MR, Schiller JH.Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504). J Clin Oncol. 2011 May 1;29(13):1709-14. Epub 2011 Mar 21.
  • Kolesar JM, Sachidanandam K, Schelman WR, Eickhoff J, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE.Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance. Exp Ther Med. 2011 Jan;2(1):119-123.
  • Ikeda R, Vermeulen LC, Lau E, Jiang Z, Sachidanandam K, Yamada K, Kolesar JM. Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells. Int J Oncol. 2011 Feb;38(2):513-9
  • Sylvester RK, Steen P, Tate JM, Mehta M, Petrich RJ, Berg A, Kolesar J. Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients. Anticancer Drugs. 2011 Jan;22(1):104-10.
  • Vanderloo JP, Pomplun ML, Vermeulen LC, Kolesar JM. Stability of unused reconstituted bortezomib in original manufacturer vials. J Oncol Pharm Pract. 2011 Dec;17(4):400-2.
  • Kolesar JM, Hoel R, Pomplun M, et al.  A Pilot, First-in-Human, Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers. Cancer Prev Res (Phila). 2010 Dec;3(12):1565-70.
  • Ikeda R, Vermeulen LC, Lau E, Jiang Z, Kavanaugh S, Yamada K, Kolesar J. Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells. Oncology Letters 2010 (in press)
  • Ikeda R, Vermeulen LC, Lau E, Jiang Z, Pomplun M, Kolesar J. Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells. Molecular Medicine Reports 2010 (in press)
  • Ikeda R, Vermeulen LC, Lau E, Jiang Z, Sachidanadam K, Yamada K, Kolesar J. Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells. Int J Oncol. 2011 Feb;38(2):513-9.
  • Ikeda R, Vermeulen LC, Lau E, Jiang Z, Kolesar J. Gemcitabine and paclitaxel suppress the production of vascular endothelial growth factor induced by deferoxamine in human non-small cell lung cancer A549 cells. Experimental and therapeutic medicine 2010;1:853-57.
  • Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD. The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. Cancer Chemother Pharmacol. 2010 Oct;66(5):973-80. Epub 2010 Feb 2
  • Kolesar J, Brundage RC, Pomplun M, Alberti D, Holen K, Traynor A, Ivy P, Wilding G. Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine((R))) in cancer patients. Cancer Chemother Pharmacol. 2010 May 4. [Epub ahead of print]
  • Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, Philip PA, Picus J, Yong WP, Horvath L, Van Hazel G, Erlichman CE, Holen KD. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol. 2010 Jul 20;28(21):3491-7. Epub 2010 Jun 7.
  • Eickhoff JC, Kyungmann Kim, Beach J, Kolesar JM, Gee JR. A Bayesian adaptive design with biomarkers for targeted therapies. Clin Trials. 2010 Oct;7(5):546-56. Epub 2010 Jun 22.
  • Delgado DC, Hank JA, Kolesar J, Lorentzen DF, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang RK, Gadbaw B, Desantes KD, London W, Seeger RC, Maris J, Sondel PM. Genotypes of NK cell KIR receptors, their ligands, and Fc{gamma} Receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010 Dec 1;70(23):9554-61.
  • Traynor AM, Lee JW, Bayer GK, Tate JM, Thomas SP, Mazurczak M, Graham DL, Kolesar JM, Schiller JH. A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. Invest New Drugs. 2010 Feb;28(1):91-7
  • Argiris, A., Buchanan, A., Brockstein, B., Kolesar, J., Ghebremichael, M., Pins, M., et al. (2009). Docetaxel and irinotecan in recurrent or metastatic head and neck cancer. Cancer, 115(19), 4504-4513.
  • Chang, J. E., Voorhees, P. M., Kolesar, J. M., Ahuja, H. G., Sanchez, F. A., Rodriguez, G. A., et al. (2009). Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: A wisconsin oncology network study. Hematological Oncology, 27(1), 11-16.
  • Ikesue H, Vermeulen LC, Roke, R, Kolesar JM. Stability of cetuximab and panitumumab in glass vials and polyvinyl chloride bags.  Am J Health Syst Pharm. 2010 Feb 1;67(3):223-6.
  • Kolesar, J., Huang, W., Eickhoff, J., Hahn, K., Alberti, D., Attia, S., et al. (2009). Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. Cancer Chemother Pharmacol, 64(1), 79-86.
  • Mulkerin, D., LoConte, N. K., Holen, K. D., Thomas, J. P., Alberti, D., Marnocha, R., et al. (2009). A phase I study of an oral simulated FOLFOX with high dose capecitabine. Investigational New Drugs, 27(5), 461-468.
  • Schelman, W. R., Morgan-Meadows, S., Marnocha, R., Lee, F., Eickhoff, J., Huang, W., et al. (2009). A phase I study of triapine (R) in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 63(6), 1147-1156.
  • Traynor, A. M., Dubey, S., Eickhoff, J. C., Kolesar, J. M., Schell, K., Huie, M. S., et al. (2009). Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: A wisconsin oncology network phase II study. J Thorac Oncol, 4(4), 522-6.
  • Traynor, A. M., Schiller, J. H., Stabile, L. P., Kolesar, J. M., Eickhoff, J. C., Dacic, S., et al. (2009). Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer, 64(1), 51-9.
  • Vermuelen, L. C., Puffer, E. B., Hallam, M., Sollinger, H. W., Hoke, R., & Kolesar, J. M. (2009). Stability of alemtuzumab for low-dose induction and test doses. American Journal of Transplantation, 9(3), 651-652.
  • Xu, Y., Kolesar, J. M., Schaaf, L. J., Drengler, R., Duan, W., Otterson, G., et al. (2009). Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies. Cancer Chemotherapy and Pharmacology, 63(6), 1073-1082.
  • Kolesar JM, Schelman WR, Geiger PG, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE. Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine((R)). J Inorg Biochem. 2008 Apr;102(4):693-8. Epub 2007 Oct 30.
  • Pomplun M, Johnson JJ, Johnston S, Kolesar JM. Stability of a heparin-free 50% ethanol lock solution for central venous catheters. J Oncol Pharm Pract. 2007 Mar;13(1):33-7.
  • Mulcahy M, Hochster H, Ryan T, Avram M, Kolesar J, Benson A. Docetaxel, oxaliplatin and 5-fluorouracil: A phase I, pharmacokinetic and pharmacogenomic study. Ann Oncol. 2008;17:96-96.
  • Loconte NK, Thomas JP, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, Kolesar J. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. Cancer Chemother Pharmacol. 2008 Mar 6;
  • Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C, Holen KD. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs 2008 Aug;26(4):369-79.
  • Liu G, Kolesar J, McNeel DG, Leith C, Schell K, Eickhoff J, Lee F, Traynor A, Marnocha R, Alberti D, Zwiebel J, Wilding G. A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2008 May 1;14(9):2732-2739.
  • Mrozek E, Kolesar J, Young D, Allen J, Villalona-Calero M, Shapiro CL. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC). Ann Oncol. 2008 Apr 11. [Epub ahead of print]
  • Dubey SD, Stephenson O, Levy DE, Miller JA, Keller SM, Schiller JH, Johnson DH, Kolesar JM.  EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thor Oncology 2006, 1: 406-412.
  • Argiris A, Hensing T, Yelandi A, Patel S, Raji A, Sturgis C, MAsters G, Gooding W, Pins M. Kolesar JM. Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non–Small-Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. J Thorac Oncol. 2006;1: 1–1-9.
  • Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, Wilding G. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 11(18):6625-33, 2005.
  • Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, Arzoomanian R, Alberti D, Wilding G. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 10(22):7450-6, 2004.
  • Kolesar JM, Pritchard SC, Kerr KM, Nicolson MC, McLeod HL. Evaluation of NQO1 Gene Expression  and Variant Allele in Human NSCLC Tumors and Matched Normal Lung Tissue. Internat J Oncol 5:1119-24, 2002.
  • Kolesar JM, Allen PG. NQOR Enhances Proliferation Inhibition by 4-Hydroxytamoxifen..  Anti-Cancer Research 2002;22:1475-78.
  • Meadows SM, Mulkerin D, Berlin J, Bailey H, Kolesar J, Warren D, Thomas JP. Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. Int J Gastrointest Cancer 32(2-3):125-8, 2002.
  • Dhurandhar NV, Israel BA, Kolesar JM, Mayhew G, Cook ME and Atkinson RL.  Transmissibility of adenovirus-induced adiposity in a chicken model.  International Journal of Obesity 2001; 25, 990 – 1006.
  • Dhurander N, Isreal B, Kolesar JM, Isreal B, Atkinson R.  Increased adiposity in animals due to human virus. International J of Obesity; 2000 24:989-996.
  • Kolesar JM, Miller JA, Dhurandar N, Atkinson R. Direct detection of AD-36 DNA. J Chrom B 2000;744:1-8.
  • Kolesar JM, Allen PA, Doran CM.  Direct detection of HIV-1 RNA by CE-LIF.  J Chrom B 1997;697:189-194.
  • Kolesar JM, Burris H, Kuhn JG.  Detection of a point mutation in NQO1 (DT diaphorase) in a patient with colon cancer. J Natl Cancer Inst 1995;87:1022 24.